Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Cancers | Free Full-Text | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells - Han - 2017 - Molecular Oncology - Wiley Online Library
Emerging therapeutic agents for lung cancer | Journal of Hematology & Oncology | Full Text
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Various Protein Kinase Inhibitors as Anticancer Agents | Encyclopedia MDPI
Cancers | Free Full-Text | Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
New Drug Product: Tabrecta - MPR
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Amivantamab mechanisms of action | Download Scientific Diagram
The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity | Request PDF
Complications following novel therapies for non‐small cell lung cancer - Skribek - 2022 - Journal of Internal Medicine - Wiley Online Library
The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice - ScienceDirect
Capmatinib (INCB28060) | 99.99%(HPLC) | Selleck | c-Met inhibitor
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Capmatinib for the treatment of non-small cell lung cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer - Lingzhi Hong, Jianjun Zhang, John V. Heymach, Xiuning Le, 2021
![PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/479267b462183671c1f9b52b4758ff507a880a2e/43-Figure11-1.png "PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar")
PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
The role of MET in chemotherapy resistance | Oncogene
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
